"Hyperaktivn\u00ED mo\u010Dov\u00FD m\u011Bch\u00FD\u0159 pat\u0159\u00ED mezi chronick\u00E1 onemocn\u011Bn\u00ED s relativn\u011B vysokou prevalenc\u00ED (9\u201342 %). Terapie je dlouhodob\u00E1, av\u0161ak pokra\u010Dov\u00E1n\u00ED l\u00E9\u010Dby (perzistence) je v\u00FDrazn\u011B ni\u017E\u0161\u00ED oproti jin\u00FDm chronick\u00FDm onemocn\u011Bn\u00EDm, jako je diabetes, hypertenze, osteopor\u00F3za apod. Z mnoha studi\u00ED vypl\u00FDv\u00E1 vysok\u00E1 variabilita dat ovlivn\u011Bn\u00E1 i n\u00E1rodn\u00EDmi podm\u00EDnkami. Proto jsme se rozhodli analyzovat re\u00E1lnou situaci v \u010Cesk\u00E9 republice. Na z\u00E1klad\u011B datab\u00E1ze zdravotn\u00ED poji\u0161\u0165ovny jsme hodnotili v obdob\u00ED dvou let p\u0159edepsanou a vyzvednutou parasympatolytickou l\u00E9\u010Dbu a jej\u00ED n\u00E1sledn\u00E9 u\u017E\u00EDv\u00E1n\u00ED po dobou jednoho roku \u2013 jej\u00ED perzistenci. Analyzov\u00E1na byla data za dvoulet\u00E9 obdob\u00ED 2009\u20132010 z\u00EDskan\u00E1 od v\u0161ech klient\u016F zdravotn\u00ED poji\u0161\u0165ovny, kter\u00FDm byla p\u0159edeps\u00E1na anticholinergn\u00ED l\u00E9\u010Dba v tomto obdob\u00ED a ti si z\u00E1rove\u0148 preskribovan\u00E9 l\u00E9ky vyzvedli. Provedli jsme srovn\u00E1n\u00ED u\u017E\u00EDv\u00E1n\u00ED l\u00E9k\u016F ve stejn\u00FDch \u010Dtvrtlet\u00EDch v dvoulet\u00E9m obdob\u00ED, a ov\u011B\u0159ili t\u00EDm stabilitu preskripce. N\u00E1sledovalo porovn\u00E1n\u00ED u\u017E\u00EDv\u00E1n\u00ED l\u00E9k\u016F ve \u010Dty\u0159ech po sob\u011B jdouc\u00EDch \u010Dtvrtlet\u00EDch. P\u0159i srovn\u00E1n\u00ED stejn\u00FDch obdob\u00ED v obou letech byl trend k m\u00EDrn\u00E9mu zv\u00FD\u0161en\u00ED preskripce, av\u0161ak rozd\u00EDl nebyl statisticky v\u00FDznamn\u00FD: 1306 (SD 56,3) oproti 1410 (SD 68,1) \u2013 p = 0,056. Procento pokra\u010Duj\u00EDc\u00ED preskripce \u2013 perzistence v obdob\u00ED jednoho roku bylo 18,5 % (min. 16,8 \u2013 max. 20,4, SD 1,56). Nejv\u011Bt\u0161\u00ED pokles nastal hned v prvn\u00EDm \u010Dtvrtlet\u00ED u\u017E\u00EDv\u00E1n\u00ED, kdy obnovilo preskripci 25,9 % pacient\u016F. Jde o jednu z prvn\u00EDch anal\u00FDz perzistence l\u00E9k\u016F na hyperaktivn\u00ED mo\u010Dov\u00FD m\u011Bch\u00FD\u0159 v \u010Cesk\u00E9 republice na z\u00E1klad\u011B dat zdravotn\u00ED poji\u0161\u0165ovny. Ukazuje se, \u017Ee je n\u00EDzk\u00E1 a na doln\u00ED hranici zahrani\u010Dn\u00EDch dat. Tato data by m\u011Bla slou\u017Eit jako referen\u010Dn\u00ED k dal\u0161\u00EDmu porovn\u00E1n\u00ED p\u0159i implementaci strategi\u00ED ovliv\u0148uj\u00EDc\u00EDch \u00FA\u010Dinnou terapii hyperaktivn\u00EDho mo\u010Dov\u00E9ho m\u011Bch\u00FD\u0159e."@cs . "Persistence of the treatment of overactive bladder in Czech Republic"@en . "1"^^ . "persistence; parasympatolytic treatment; overactive bladder"@en . "Overactive bladder is chronic disease with high prevalence rate (9\u201342%). This syndrome requires longterm therapy but the persistence of this treatment in comparison with other chronic diseases as diabetes, hypertension, osteoporosis etc. is low. Accorging many studies the persistence variability is high and could be influenced by regional circumstanses. We desided to analyze real situation in parasympatolytics persitance in two years period in Czech Republic based on registry of health insurance company. We analyzed data between 2009 and 2010 of all clients of health insurance company where they fullfil their prescribtion. We analyzed the persistence in one year period in different periods of the year and within one year. In comparison of the same period between those two year there was a trend of increase of prescription but it was not significant: 1306 (SD 56.3) vs 1410 (SD 68.1) \u2013 p = 0.056. Prescription of the treatment after one year was only 18.5% (min. 16.8 \u2013 max. 20.4, SD 1.56). Major drop-out was in first 3-month period where renewed their prescription only 25.9% of the patients. This one of the first study analyzing the parasympatolytics prescription persistence based on registry of health insurence company. The persistence in Czech Republic was low but withing the range of international data. Those result should be used as a reference data for comparison of the effect of varius strategies influencing the overactive bladder treatment."@en . . "Hyperaktivn\u00ED mo\u010Dov\u00FD m\u011Bch\u00FD\u0159 pat\u0159\u00ED mezi chronick\u00E1 onemocn\u011Bn\u00ED s relativn\u011B vysokou prevalenc\u00ED (9\u201342 %). Terapie je dlouhodob\u00E1, av\u0161ak pokra\u010Dov\u00E1n\u00ED l\u00E9\u010Dby (perzistence) je v\u00FDrazn\u011B ni\u017E\u0161\u00ED oproti jin\u00FDm chronick\u00FDm onemocn\u011Bn\u00EDm, jako je diabetes, hypertenze, osteopor\u00F3za apod. Z mnoha studi\u00ED vypl\u00FDv\u00E1 vysok\u00E1 variabilita dat ovlivn\u011Bn\u00E1 i n\u00E1rodn\u00EDmi podm\u00EDnkami. Proto jsme se rozhodli analyzovat re\u00E1lnou situaci v \u010Cesk\u00E9 republice. Na z\u00E1klad\u011B datab\u00E1ze zdravotn\u00ED poji\u0161\u0165ovny jsme hodnotili v obdob\u00ED dvou let p\u0159edepsanou a vyzvednutou parasympatolytickou l\u00E9\u010Dbu a jej\u00ED n\u00E1sledn\u00E9 u\u017E\u00EDv\u00E1n\u00ED po dobou jednoho roku \u2013 jej\u00ED perzistenci. Analyzov\u00E1na byla data za dvoulet\u00E9 obdob\u00ED 2009\u20132010 z\u00EDskan\u00E1 od v\u0161ech klient\u016F zdravotn\u00ED poji\u0161\u0165ovny, kter\u00FDm byla p\u0159edeps\u00E1na anticholinergn\u00ED l\u00E9\u010Dba v tomto obdob\u00ED a ti si z\u00E1rove\u0148 preskribovan\u00E9 l\u00E9ky vyzvedli. Provedli jsme srovn\u00E1n\u00ED u\u017E\u00EDv\u00E1n\u00ED l\u00E9k\u016F ve stejn\u00FDch \u010Dtvrtlet\u00EDch v dvoulet\u00E9m obdob\u00ED, a ov\u011B\u0159ili t\u00EDm stabilitu preskripce. N\u00E1sledovalo porovn\u00E1n\u00ED u\u017E\u00EDv\u00E1n\u00ED l\u00E9k\u016F ve \u010Dty\u0159ech po sob\u011B jdouc\u00EDch \u010Dtvrtlet\u00EDch. P\u0159i srovn\u00E1n\u00ED stejn\u00FDch obdob\u00ED v obou letech byl trend k m\u00EDrn\u00E9mu zv\u00FD\u0161en\u00ED preskripce, av\u0161ak rozd\u00EDl nebyl statisticky v\u00FDznamn\u00FD: 1306 (SD 56,3) oproti 1410 (SD 68,1) \u2013 p = 0,056. Procento pokra\u010Duj\u00EDc\u00ED preskripce \u2013 perzistence v obdob\u00ED jednoho roku bylo 18,5 % (min. 16,8 \u2013 max. 20,4, SD 1,56). Nejv\u011Bt\u0161\u00ED pokles nastal hned v prvn\u00EDm \u010Dtvrtlet\u00ED u\u017E\u00EDv\u00E1n\u00ED, kdy obnovilo preskripci 25,9 % pacient\u016F. Jde o jednu z prvn\u00EDch anal\u00FDz perzistence l\u00E9k\u016F na hyperaktivn\u00ED mo\u010Dov\u00FD m\u011Bch\u00FD\u0159 v \u010Cesk\u00E9 republice na z\u00E1klad\u011B dat zdravotn\u00ED poji\u0161\u0165ovny. Ukazuje se, \u017Ee je n\u00EDzk\u00E1 a na doln\u00ED hranici zahrani\u010Dn\u00EDch dat. Tato data by m\u011Bla slou\u017Eit jako referen\u010Dn\u00ED k dal\u0161\u00EDmu porovn\u00E1n\u00ED p\u0159i implementaci strategi\u00ED ovliv\u0148uj\u00EDc\u00EDch \u00FA\u010Dinnou terapii hyperaktivn\u00EDho mo\u010Dov\u00E9ho m\u011Bch\u00FD\u0159e." . "Martan, A." . . "CZ - \u010Cesk\u00E1 republika" . . "RIV/00843989:_____/13:00103284!RIV14-MZ0-00843989" . "3" . . "Finsterle, V." . "5"^^ . . . "78" . "Perzistence u\u017E\u00EDv\u00E1n\u00ED l\u00E9\u010Dby hyperaktivn\u00EDho mo\u010Dov\u00E9ho m\u011Bch\u00FD\u0159e v \u010Cesk\u00E9 republice" . . . "95937" . . . "\u010Cesk\u00E1 gynekologie" . "RIV/00843989:_____/13:00103284" . "\u0160vab\u00EDk, K." . "1210-7832" . . . . "N, V" . "Perzistence u\u017E\u00EDv\u00E1n\u00ED l\u00E9\u010Dby hyperaktivn\u00EDho mo\u010Dov\u00E9ho m\u011Bch\u00FD\u0159e v \u010Cesk\u00E9 republice"@cs . . "[B696FE5BA69E]" . "Persistence of the treatment of overactive bladder in Czech Republic"@en . "Perzistence u\u017E\u00EDv\u00E1n\u00ED l\u00E9\u010Dby hyperaktivn\u00EDho mo\u010Dov\u00E9ho m\u011Bch\u00FD\u0159e v \u010Cesk\u00E9 republice" . . "Perzistence u\u017E\u00EDv\u00E1n\u00ED l\u00E9\u010Dby hyperaktivn\u00EDho mo\u010Dov\u00E9ho m\u011Bch\u00FD\u0159e v \u010Cesk\u00E9 republice"@cs . "Krhut, Jan" . . "4"^^ .